Abstract
Heart failure (HF) is characterized by abnormal mitochondrial calcium (Ca2+) handling, energy failure and impaired mitophagy resulting in contractile dysfunction and myocyte death. We have previously shown that the 18-kDa mitochondrial translocator protein of the outer mitochondrial membrane (TSPO) can modulate mitochondrial Ca2+ uptake. Experiments were designed to test the role of the TSPO in a murine pressure-overload model of HF induced by transverse aortic constriction (TAC). Conditional, cardiac-specific TSPO knockout (KO) mice were generated using the Cre-loxP system. TSPO-KO and wild-type (WT) mice underwent TAC for 8 weeks. TAC-induced HF significantly increased TSPO expression in WT mice, associated with a marked reduction in systolic function, mitochondrial Ca2+ uptake, complex I activity and energetics. In contrast, TSPO-KO mice undergoing TAC had preserved ejection fraction, and exhibited fewer clinical signs of HF and fibrosis. Mitochondrial Ca2+ uptake and energetics were restored in TSPO KO mice, associated with decreased ROS, improved complex I activity and preserved mitophagy. Thus, HF increases TSPO expression, while preventing this increase limits the progression of HF, preserves ATP production and decreases oxidative stress, thereby preventing metabolic failure. These findings suggest that pharmacological interventions directed at TSPO may provide novel therapeutics to prevent or treat HF.
Highlights
Mitochondrial Ca2+ serves as a regulator of energy production[6,14,15]
Our previous work showed that altering translocator protein (TSPO) activity with a pharmacologic ligand protoporphyrin IX decreased Ca2+ uptake in mitochondria isolated from cardiac tissue by decreasing the open probability of VDAC21, which raises the possibility that TSPO may play a role in mitochondrial Ca2+ handling
TSPO expression is upregulated in pressure overload-induced heart failure
Summary
Mitochondrial Ca2+ serves as a regulator of energy production[6,14,15]. during HF, mitochondrial Ca2+ uptake is typically reduced[3,14,16], which can impact the production of energy and contribute to the pathogenesis of HF. The objectives of the present study were to test the hypotheses that: a) HF increases expression of TSPO, with a concomitant decrease in inward mitochondrial Ca2+ entry and systolic function; and b) genetic modulation of the TSPO could normalize mitochondrial Ca2+ uptake and prevent the abnormalities in cardiac structure and function evident in HF, by normalizing cellular energetics and redox balance inside cardiomyocytes. These hypotheses were tested using a cardiomyocyte-specific, conditional knockout of the TSPO in a murine model of pressure-overload HF. These data suggest that TSPO can be a potential pharmacological target to correct the abnormalities in mitochondrial Ca2+ transport and mitochondrial bioenergetics associated with HF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.